{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:21:30Z","timestamp":1783034490149,"version":"3.54.6"},"reference-count":66,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2694843","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:07:17Z","timestamp":1783033637000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan\u2019s pediatric National Immunization Program and impacts of a delayed implementation"],"prefix":"10.1080","volume":"22","author":[{"given":"Ya-Min","family":"Yang","sequence":"first","affiliation":[{"name":"Pfizer Inc","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Ta","sequence":"additional","affiliation":[{"name":"Cytel, Inc","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vinand","sequence":"additional","affiliation":[{"name":"Cytel, Inc","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Rutherford","sequence":"additional","affiliation":[{"name":"Cytel, Inc","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Huang","sequence":"additional","affiliation":[{"name":"Global Value and Evidence, Vaccines, Pfizer Inc","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-778FR"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2015.4.2.121"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.09.002"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10379-z"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.061"},{"key":"e_1_3_6_7_1","unstructured":"Taiwan Centers for Disease Control (TCDC). Current immunization schedule in Taiwan. 2019 [accessed 2025 Apr]. https:\/\/www.cdc.gov.tw\/File\/Get\/1dqIAWsT60hSkcHf8-jMQQ."},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2022.08.018"},{"key":"e_1_3_6_9_1","unstructured":"Taiwan Centers for Disease Control (TCDC). Current children immunization schedule (verison: January 2024). 2024 [accessed 2025 Feb]. https:\/\/www.cdc.gov.tw\/File\/Get\/xrvB0rEniERWTvRq-p_pww."},{"key":"e_1_3_6_10_1","unstructured":"Pfizer Inc. U.S. FDA approves PREVNAR 20\u00ae Pfizer\u2019s 20-valent pneumococcal conjugate vaccine for infants and children. 2023 [accessed 2024 Mar 13]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal."},{"key":"e_1_3_6_11_1","unstructured":"European Medicines Agency (EMA). European public assessment report (EPAR). Prevenar 20 (previously Apexxnar). 2022 [accessed 2024 Mar 13]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevenar-20-previously-apexxnar."},{"key":"e_1_3_6_12_1","unstructured":"Taiwan Food and Drug Administration. Ministry of Health and Family Planning Commission's Epidemic Prevention and Control Order No. 001268. 2024 [accessed 2025 May]. https:\/\/lmspiq.fda.gov.tw\/web\/DRPIQ\/DRPIQ1000Result?licBaseId=EC9FBF94-F2A8-4E9A-8A3D-829C8DC9CF40."},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2257426"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-00977-4"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.06.011"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2400751"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01109-2"},{"key":"e_1_3_6_18_1","unstructured":"Taiwan Center For Drug Evaluation. Guidelines for cost-effectiveness analysis methodology in health technology assessment. 2024 [accessed 2025 Apr]. https:\/\/www.cde.org.tw\/media\/001fagoj\/%E9%86%AB%E7%99%82%E7%A7%91%E6%8A%80%E8%A9%95%E4%BC%B0%E6%88%90%E6%9C%AC%E6%95%88%E7%9B%8A%E8%A9%95%E4%BC%B0cea%E6%96%B9%E6%B3%95%E5%AD%B8%E6%8C%87%E5%BC%95_2024-08-12.pdf."},{"key":"e_1_3_6_19_1","unstructured":"Taiwan Center For Drug Evaluation. Introduction of economic evaluation method for vaccine. 2022 [accessed 2025 Apr]. https:\/\/www.cde.org.tw\/media\/1v4jti4k\/2022-%E7%AC%AC135%E6%9C%9F-%E6%B3%95%E8%A6%8F%E8%AB%96%E6%96%87_%E7%96%AB%E8%8B%97%E7%B6%93%E6%BF%9F%E8%A9%95%E4%BC%B0%E6%96%B9%E6%B3%95%E7%B0%A1%E4%BB%8B_hta-%E7%B0%A1%E4%BC%B6%E8%93%81.pdf?mediaDL=true."},{"key":"e_1_3_6_20_1","unstructured":"Taiwan Centers for Disease Control (TCDC). Vaccination statistics; 2023 [accessed 2024 Oct]. https:\/\/www.cdc.gov.tw\/Category\/MPage\/S2UF2-VuMgfzgzpy7qdvlA."},{"key":"e_1_3_6_21_1","unstructured":"Taiwan Centers for Disease Control (TCDC). To fully prevent invasive pneumococcal infection approximately 6 000 high-risk individuals who are eligible for public funding are requested to complete the second dose of vaccination as soon as possible. We also remind that the public funding eligibility has been expanded to include Indigenous people aged 55\u201364. Those who have not yet been vaccinated are requested to actively vaccinate to enhance their immune protection. 2024 [accessed 2025 Feb]. https:\/\/www.cdc.gov.tw\/Bulletin\/Detail\/KEt1F0iJkakW-2lMPmblEQ?typeid=9."},{"key":"e_1_3_6_22_1","unstructured":"Taiwan Centers for Disease Control (TCDC). MOHW110-CDC-C-315-124115: molecular epidemiology of vaccine-preventable Streptococcus pneumoniae. 2021 [accessed 2025 Apr]. https:\/\/ah.cdc.gov.tw\/planOne?pid=1554."},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-020-00225-9"},{"key":"e_1_3_6_24_1","unstructured":"Department of Household Registration Ministry of the Interior (Taiwan). Population by sex and 5 year age group for counties and cities. 2023 [accessed 2024 Oct]. https:\/\/www.ris.gov.tw\/app\/portal\/346."},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.10.058"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.014"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.003"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-597"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2302-3"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00325-2015"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3651-0"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2509"},{"key":"e_1_3_6_33_1","unstructured":"National Statistics Republic of China (Taiwan). CPI change rate. 2026 [accessed 2024 Oct]. https:\/\/eng.stat.gov.tw\/Point.aspx?sid=t.2&n=4201&sms=11713."},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2011.10.006"},{"key":"e_1_3_6_35_1","unstructured":"Taiwan National Health Insurance Administration (NHIA). Medical service reimbursed item. 2023 [accessed 2025 May]. https:\/\/www.nhi.gov.tw\/ch\/cp-5943-f1cce-2821-1.html."},{"key":"e_1_3_6_36_1","unstructured":"National Development Council Population Projections for the R.O.C (Taiwan). Births and deaths - births. 2024 [accessed 2024 Oct]. https:\/\/pop-proj.ndc.gov.tw\/main_en\/Custom_Fast_Statistics_Search.aspx?n=138&sms=0&d=H08&m=81&Create=1."},{"key":"e_1_3_6_37_1","unstructured":"Ministry of the Interior Republic of China (Taiwan). Taiwan life tables. 2025 [accessed 2025 Apr]. https:\/\/www.moi.gov.tw\/english\/cl.aspx?n=7779."},{"key":"e_1_3_6_38_1","unstructured":"Taiwan Centers for Disease Control (TCDC). MOHW107-CDC-C-315-112112_CDC: surveillance of serotype and antigenic variation for vaccine-preventable bacterial pathogens. 2018 [accessed 2025 Apr]. https:\/\/ah.cdc.gov.tw\/planOne?pid=1274."},{"key":"e_1_3_6_39_1","unstructured":"Taiwan Centers for Disease Control (TCDC). MOHW108-CDC-C-315-122112_CDC: surveillance of serotype and antigenic variation for vaccine-preventable bacterial pathogens. 2019 [accessed 2025 Apr]. https:\/\/ah.cdc.gov.tw\/planOne?pid=1367."},{"key":"e_1_3_6_40_1","unstructured":"Taiwan Centers for Disease Control (TCDC). MOHW109-CDC-C-315-114116: molecular epidemiology of vaccine-preventable Streptococcus pneumoniae. 2020 [accessed 2025 Apr]. https:\/\/ah.cdc.gov.tw\/planOne?pid=1449."},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.025"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7137a3"},{"key":"e_1_3_6_43_1","unstructured":"Pfizer Inc. Data from Pfizer\u2019s adult and pediatric clinical trial programs for 20-valent pneumococcal conjugate vaccine presented at IDWeek 2020. 2020 [accessed 2025 Feb]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/data-pfizers-adult-and-pediatric-clinical-trial-programs-20."},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000003277"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2134120"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00538-z"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1809266"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11071168"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.05.011"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200003000-00003"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200209000-00005"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000232706.35674.2f"},{"key":"e_1_3_6_53_1","unstructured":"Taiwan Centers for Disease Control (TCDC). Invasive pneumococcal disease. 2017 [accessed 2025 Feb]. https:\/\/www.cdc.gov.tw\/En\/Category\/ListContent\/bg0g_VU_Ysrgkes_KRUDgQ?uaid=lS42udX_s0u2fN0qLcdrnw."},{"key":"e_1_3_6_54_1","unstructured":"Taiwan Centers for Disease Control (TCDC). MOHW106-CDC-C-315-133132: Taiwan Centers for Disease Control (CDC). Surveillance and epidemiology of multidrug-resistant Streptococcus. 2017 [accessed 2025 Apr]. https:\/\/ah.cdc.gov.tw\/planOne?pid=1226."},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(18)30052-5"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.022"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00183614"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.057"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00798-x"},{"key":"e_1_3_6_60_1","unstructured":"Exchange Rates. US dollar to Taiwan dollar history. 2025 [accessed 2026 May]. https:\/\/www.exchangerates.org.uk\/USD-TWD-spot-exchange-rates-history-2025.html."},{"key":"e_1_3_6_61_1","unstructured":"International Monetary Fund. GDP per capita current prices. [accessed 2026 May]. https:\/\/www.imf.org\/external\/datamapper\/NGDPDPC@WEO\/ADVEC\/WEOWORLD\/CHN\/TWN."},{"key":"e_1_3_6_62_1","unstructured":"Taiwan Food and Drug Administration. Prevenar 20 pneumococcal 20-valent conjugate vaccine (20vPnC). 2024 [accessed 2025 Apr]. https:\/\/www.fda.gov.tw\/tc\/includes\/GetFile.ashx?id=f638747767069838018&type=2&cid=48283."},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2025.2521445"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2515596"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2025.105084"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01108-3"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2475594"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2694843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2026.2694843","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2694843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:07:26Z","timestamp":1783033646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2694843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2694843"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2694843","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2694843"}}